Effectiveness of nanofat in treatment-refractory penile lichen sclerosus: results from a pilot retrospective single-center case series.
Brambilla M., Benzecry V., Maronese CA., Barberi F., Cusini M., Boero V.
Retrospective Study, published in Ital J Dermatol Venerol (2025) — summary generated from the PubMed abstract.
Early human evidence such as case series or small samples is exploring possible benefits.
- Level A · Stronger Clinical Evidence
- Level B · Emerging clinical evidence with positive signals
- Level C · Early human research exploring benefits
- Level D · Scientific groundwork from lab and animal studies
- Emerging · Emerging topic under active research
This page is generated from the PubMed record. The Thai description is an automated summary of bibliographic fields and the abstract, not a full translation, and is not medical advice.
- Study type
- Retrospective Study
- Journal
- Ital J Dermatol Venerol (2025)
- Country
- Italy
- Reported sample size
- —
- Source database
- PubMed
- PMID
- 40248963
- DOI
- 10.23736/S2784-8671.25.08247-7
- Citations
- 1
Abstract (original English)
Background Penile lichen sclerosus (PLS) is a chronic inflammatory skin disorder that may lead to progressive architectural distortion of male genitalia, with a dramatic impact on quality of life and a high unmet therapeutic need. In keeping with vulvar disease, nanofat grafting could represent a viable option in this setting. Methods Patients aged 18 years or above with biopsy-proven, medical and/or surgical treatment-resistant PLS were offered nanofat and were evaluated at baseline, 1 and 24 months. Results Fourteen male patients with a median age of 46 years (interquartile range [IQR]: 37.25-51.5) were included. Median modified Investigator Global Assessment (mIGA) scores changed from 18 (IQR: 14.75-22.75) at the baseline, to 15.5 (IQR: 13-20.25) at 1 month (P=0.002), to 14 (IQR: 8-17) at 24 months (P=0.001). mIGA subscores for erythema improved significantly after just one month (P=0.002) and the improvement was maintained throughout the 24 months of follow-up (P=0.001). At 24 months, a statistically significant reduction relative to the baseline was demonstrated also for itch (P=0.014), burning sensation (P=0.02) and dyspareunia (P=0.02). Median Patient Global Impression of Change at 24 months was 6 (IQR: 4.75-6.25) ("much improved"). No adverse effects or complications were recorded. Conclusions Nanofat grafting not only seems to improve genital tissue quality, but appear
What this study does not prove
- • This study does not prove SVF is an approved treatment or a replacement for standard care.
- • Without an adequate control group, treatment effects cannot be separated from other factors.
Evidence level
Early human evidence such as case series or small samples is exploring possible benefits.
How we grade evidenceBrowse all related research
Filter the research library by this study's title keywords, author, or publication year.